OABI - NASDAQ
OmniAb, Inc.
$2.62
-4.6%OmniAb, Inc., a biotechnology company, provides therapeutic antibody discovery technologies in the United States. The company's discovery platform provides industry partners access to the diverse antibody repertoires and screening technologies to enable discovery of next-generation therapeutics. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTaur that features unique structural attributes of cow antibodies for complex targets. The company was founded in 2012 and is headquartered in Emeryville, California.
At a Glance
Live Snapshotoabi
Selling, General and Administrative Expenses
Last Annual Value
29.21M
3-Year CAGR
5%
5-Year CAGR
23%
10-Year CAGR
13%
OmniAb, Inc. Competitors Analysis of Selling, General and Administrative Expenses
| Company | Selling, General and Administrative Expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
OmniAb, Inc. NASDAQ:OABI | 29.21M | -4.3% | 11.5% | N/A | |
 Invivyd, Inc. NASDAQ:IVVD | 66.93M | 10.9% | 12.9% | N/A | |
 Neonc Technologies Holdings, Inc. NASDAQ:NTHI | 42.85M | 132.8% | 75.2% | N/A | |
 Cassava Sciences, Inc. NASDAQ:SAVA | 68.80M | 60.8% | 53.6% | 28.1% | |
 Vor Biopharma Inc. NASDAQ:VOR | 50.11M | 16.5% | 18.5% | N/A | |
 Corbus Pharmaceuticals Holdings, Inc. NASDAQ:CRBP | 15.21M | 3.0% | -5.7% | 8.9% | |
 Orchestra BioMed Holdings, Inc. NASDAQ:OBIO | 26.91M | 9.9% | 27.7% | N/A | |
 Pyxis Oncology, Inc. NASDAQ:PYXS | 22.19M | -12.0% | 3.5% | N/A | |
 Codexis, Inc. NASDAQ:CDXS | 47.07M | -4.0% | -0.9% | 6.4% | |
 Sangamo Therapeutics, Inc. NASDAQ:SGMO | 34.89M | -17.1% | -11.2% | 2.9% | |
 Armata Pharmaceuticals, Inc. AMEX:ARMP | 12.41M | 5.1% | 8.4% | 4.0% |
OmniAb, Inc. Fair Value Envelope
Related Guides
Continue your OABI research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.